Boston Scientific shares drop 50% amid slower growth and competition, but valuation looks attractive now.

Boston Scientific's share price has fallen by 50% due to slowing growth in key areas like electrophysiology and Watchman, driven by increased competition, reimbursement cuts, and weaker clinical trial results. Management now expects revenue growth below 10%, around 6.5%-8% for the year, but an annualized growth of 7.5% over five years with improving margins is still anticipated. The stock is considered undervalued in the high $50s to low $60s range, but a positive re-rating depends on consistent execution and no further downward revisions to guidance.